Current status of antigen-specific T-cell immunotherapy for advanced renal-cell carcinoma

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34. doi:10.3322/caac.21551.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999;17(8):2530–40. doi:10.1200/JCO.1999.17.8.2530.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J Urol. 2000;163(2):408–17. doi:10.1016/S0022-5347(05)67889-5.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Tannir NM, McDermott DF, Aren Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthelemy P, Porta C, George S, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378(14):1277–90. doi:10.1056/NEJMoa1712126.
   PubMed Web of Science ®Google Scholar
• Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, Pouliot F, Alekseev B, Soulieres D, Melichar B, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1116–27. doi:10.1056/NEJMoa1816714.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT, Venugopal B, Kollmannsberger C, Negrier S, Uemura M, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1103–15. doi:10.1056/NEJMoa1816047.
   PubMed Web of Science ®Google Scholar
• Bumpus HC. The apparent disappearance of pulmonary metastasis in a case of hypernephroma following nephrectomy. J Urol. 1928;20(2):185–92. doi:10.1016/S0022-5347(17)73147-3.
   Google Scholar
• Janiszewska AD, Poletajew S, Wasiutynski A. Spontaneous regression of renal cell carcinoma. Contemp Oncol (Pozn). 2013;17(2):123–27. doi:10.5114/wo.2013.34613.
   PubMed Web of Science ®Google Scholar
• Hobohm U. Fever therapy revisited. Br J Cancer. 2005;92(3):421–25. doi:10.1038/sj.bjc.6602386.
   PubMed Web of Science ®Google Scholar
• Gastl G, Ebert T, Finstad CL, Sheinfeld J, Gomahr A, Aulitzky W, Bander NH. Major histocompatibility complex class i and class ii expression in renal cell carcinoma and modulation by interferon gamma. J Urol. 1996;155(1):361–67. doi:10.1016/S0022-5347(01)66661-8.
   PubMed Web of Science ®Google Scholar
• Finke JH, Rayman P, Edinger M, Tubbs RR, Stanley J, Klein E, Bukowski R. Characterization of a human renal cell carcinoma specific cytotoxic cd8+ t cell line. J Immunother. 1991–1992;11(1):1–11. doi:10.1097/00002371-199201000-00001.
   Web of Science ®Google Scholar
• Schendel DJ, Gansbacher B, Oberneder R, Kriegmair M, Hofstetter A, Riethmuller G, Segurado OG. Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes. I. Hla-a2-restricted recognition of autologous and allogeneic tumor lines. J Immunol. 1993;151:4209–20.
   PubMed Web of Science ®Google Scholar
• Brandle D, Brasseur F, Weynants P, Boon T, Van den Eynde B. A mutated hla-a2 molecule recognized by autologous cytotoxic t lymphocytes on a human renal cell carcinoma. J Exp Med. 1996;183(6):2501–08. doi:10.1084/jem.183.6.2501.
   PubMed Web of Science ®Google Scholar
• Gaudin C, Kremer F, Angevin E, Scott V, Triebel F. A hsp70–2 mutation recognized by ctl on a human renal cell carcinoma. J Immunol. 1999;162:1730–38.
   PubMed Web of Science ®Google Scholar
• Gaugler B, Brouwenstijn N, Vantomme V, Szikora JP, Van der Spek CW, Patard JJ, Boon T, Schrier P, Van den Eynde BJ. A new gene coding for an antigen recognized by autologous cytolytic t lymphocytes on a human renal carcinoma. Immunogenetics. 1996;44(5):323–30. doi:10.1007/BF02602776.
   PubMed Web of Science ®Google Scholar
• Morel S, Levy F, Burlet-Schiltz O, Brasseur F, Probst-Kepper M, Peitrequin AL, Monsarrat B, Van Velthoven R, Cerottini JC, Boon T, et al. Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells. Immunity. 2000;12(1):107–17. doi:10.1016/S1074-7613(00)80163-6.
   PubMed Web of Science ®Google Scholar
• Probst-Kepper M, Stroobant V, Kridel R, Gaugler B, Landry C, Brasseur F, Cosyns JP, Weynand B, Boon T, Van den Eynde BJ. An alternative open reading frame of the human macrophage colony-stimulating factor gene is independently translated and codes for an antigenic peptide of 14 amino acids recognized by tumor-infiltrating cd8 t lymphocytes. J Exp Med. 2001;193(10):1189–98. doi:10.1084/jem.193.10.1189.
   PubMed Web of Science ®Google Scholar
• Ronsin C, Chung-Scott V, Poullion I, Aknouche N, Gaudin C, Triebel F. A non-aug-defined alternative open reading frame of the intestinal carboxyl esterase mrna generates an epitope recognized by renal cell carcinoma-reactive tumor-infiltrating lymphocytes in situ. J Immunol. 1999;163:483–90.
   PubMed Web of Science ®Google Scholar
• Van Den Eynde BJ, Gaugler B, Probst-Kepper M, Michaux L, Devuyst O, Lorge F, Weynants P, Boon T. A new antigen recognized by cytolytic t lymphocytes on a human kidney tumor results from reverse strand transcription. J Exp Med. 1999;190(12):1793–800. doi:10.1084/jem.190.12.1793.
   PubMed Web of Science ®Google Scholar
• Hanada K, Yewdell JW, Yang JC. Immune recognition of a human renal cancer antigen through post-translational protein splicing. Nature. 2004;427(6971):252–56. doi:10.1038/nature02240.
   PubMed Web of Science ®Google Scholar
• Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol. 1995;13(3):688–96. doi:10.1200/JCO.1995.13.3.688.
   PubMed Web of Science ®Google Scholar
• Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, Abrams J, Sznol M, Parkinson D, Hawkins M, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999;17(7):2105–16. doi:10.1200/JCO.1999.17.7.2105.
   PubMed Web of Science ®Google Scholar
• Belldegrun AS, Klatte T, Shuch B, LaRochelle JC, Miller DC, Said JW, Riggs SB, Zomorodian N, Kabbinavar FF, Dekernion JB, et al. Cancer-specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989–2005): a benchmark for emerging targeted cancer therapies. Cancer. 2008;113(9):2457–63. doi:10.1002/cncr.23851.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002;20(1):289–96. doi:10.1200/JCO.2002.20.1.289.
   PubMed Web of Science ®Google Scholar
• Palmer PA, Vinke J, Philip T, Negrier S, Atzpodien J, Kirchner H, Oskam R, Franks CR, Von der Maase H, Thatcher N. Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2. Ann Oncol. 1992;3(6):475–80. doi:10.1093/oxfordjournals.annonc.a058239.
   PubMed Web of Science ®Google Scholar
• Fossa SD, Kramar A, Droz JP. Prognostic factors and survival in patients with metastatic renal cell carcinoma treated with chemotherapy or interferon-alpha. Eur J Cancer. 1994;30A(9):1310–14. doi:10.1016/0959-8049(94)90179-1.
   PubMed Web of Science ®Google Scholar
• Varn FS, Wang Y, Mullins DW, Fiering S, Cheng C. Systematic pan-cancer analysis reveals immune cell interactions in the tumor microenvironment. Cancer Res. 2017;77(6):1271–82. doi:10.1158/0008-5472.CAN-16-2490.
   PubMed Web of Science ®Google Scholar
• Chevrier S, Levine JH, Zanotelli VRT, Silina K, Schulz D, Bacac M, Ries CH, Ailles L, Jewett MAS, Moch H, et al. An immune atlas of clear cell renal cell carcinoma. Cell. 2017;169(4):736–749 e718. doi:10.1016/j.cell.2017.04.016.
   PubMed Web of Science ®Google Scholar
• Rooney MS, Shukla SA, Wu CJ, Getz G, Hacohen N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell. 2015;160(1–2):48–61. doi:10.1016/j.cell.2014.12.033.
   PubMed Web of Science ®Google Scholar
• Giraldo NA, Becht E, Pages F, Skliris G, Verkarre V, Vano Y, Mejean A, Saint-Aubert N, Lacroix L, Natario I, et al. Orchestration and prognostic significance of immune checkpoints in the microenvironment of primary and metastatic renal cell cancer. Clin Cancer Res. 2015;21(13):3031–40. doi:10.1158/1078-0432.CCR-14-2926.
   PubMed Web of Science ®Google Scholar
• Remark R, Alifano M, Cremer I, Lupo A, Dieu-Nosjean MC, Riquet M, Crozet L, Ouakrim H, Goc J, Cazes A, et al. Characteristics and clinical impacts of the immune environments in colorectal and renal cell carcinoma lung metastases: influence of tumor origin. Clin Cancer Res. 2013;19(15):4079–91. doi:10.1158/1078-0432.CCR-12-3847.
   PubMed Web of Science ®Google Scholar
• Kondo T, Nakazawa H, Ito F, Hashimoto Y, Osaka Y, Futatsuyama K, Toma H, Tanabe K. Favorable prognosis of renal cell carcinoma with increased expression of chemokines associated with a th1-type immune response. Cancer Sci. 2006;97(8):780–86. doi:10.1111/j.1349-7006.2006.00231.x.
   PubMed Web of Science ®Google Scholar
• Senbabaoglu Y, Gejman RS, Winer AG, Liu M, Van Allen EM, de Velasco G, Miao D, Ostrovnaya I, Drill E, Luna A, et al. Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger rna signatures. Genome Biol. 2016;17(1):231. doi:10.1186/s13059-016-1092-z.
   PubMed Web of Science ®Google Scholar
• Ghatalia P, Gordetsky J, Kuo F, Dulaimi E, Cai KQ, Devarajan K, Bae S, Naik G, Chan TA, Uzzo R, et al. Prognostic impact of immune gene expression signature and tumor infiltrating immune cells in localized clear cell renal cell carcinoma. J Immunother Cancer. 2019;7(1):139. doi:10.1186/s40425-019-0621-1.
   PubMed Web of Science ®Google Scholar
• Nakano O, Sato M, Naito Y, Suzuki K, Orikasa S, Aizawa M, Suzuki Y, Shintaku I, Nagura H, Ohtani H. Proliferative activity of intratumoral cd8(+) t-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. Cancer Res. 2001;61:5132–36.
   PubMed Web of Science ®Google Scholar
• Gaudin C, Dietrich PY, Robache S, Guillard M, Escudier B, Lacombe MJ, Kumar A, Triebel F, Caignard A. In vivo local expansion of clonal t cell subpopulations in renal cell carcinoma. Cancer Res. 1995;55:685–90.
   PubMed Web of Science ®Google Scholar
• Weidmann E, Logan TF, Yasumura S, Kirkwood JM, Trucco M, Whiteside TL. Evidence for oligoclonal t-cell response in a metastasis of renal cell carcinoma responding to vaccination with autologous tumor cells and transfer of in vitro-sensitized vaccine-draining lymph node lymphocytes. Cancer Res. 1993;53:4745–49.
   PubMed Web of Science ®Google Scholar
• Massa C, Robins H, Desmarais C, Riemann D, Fahldieck C, Fornara P, Seliger B. Identification of patient-specific and tumor-shared t cell receptor sequences in renal cell carcinoma patients. Oncotarget. 2017;8(13):21212–28. doi:10.18632/oncotarget.15064.
   PubMedGoogle Scholar
• Prinz PU, Mendler AN, Masouris I, Durner L, Oberneder R, Noessner E. High dgk-alpha and disabled mapk pathways cause dysfunction of human tumor-infiltrating cd8+ t cells that is reversible by pharmacologic intervention. J Immunol. 2012;188(12):5990–6000. doi:10.4049/jimmunol.1103028.
   PubMed Web of Science ®Google Scholar
• Noessner E, Brech D, Mendler AN, Masouris I, Schlenker R, Prinz PU. Intratumoral alterations of dendritic-cell differentiation and cd8(+) t-cell anergy are immune escape mechanisms of clear cell renal cell carcinoma. Oncoimmunology. 2012;1(8):1451–53. doi:10.4161/onci.21356.
   PubMed Web of Science ®Google Scholar
• Krummel MF, Allison JP. Cd28 and ctla-4 have opposing effects on the response of t cells to stimulation. J Exp Med. 1995;182(2):459–65. doi:10.1084/jem.182.2.459.
   PubMed Web of Science ®Google Scholar
• Krummel MF, Allison JP. Ctla-4 engagement inhibits il-2 accumulation and cell cycle progression upon activation of resting t cells. J Exp Med. 1996;183(6):2533–40. doi:10.1084/jem.183.6.2533.
   PubMed Web of Science ®Google Scholar
• Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, et al. Tumor-associated b7-h1 promotes t-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8(8):793–800. doi:10.1038/nm730.
   PubMed Web of Science ®Google Scholar
• Fife BT, Pauken KE, Eagar TN, Obu T, Wu J, Tang Q, Azuma M, Krummel MF, Bluestone JA. Interactions between pd-1 and pd-l1 promote tolerance by blocking the tcr-induced stop signal. Nat Immunol. 2009;10(11):1185–92. doi:10.1038/ni.1790.
   PubMed Web of Science ®Google Scholar
• Thompson RH, Kuntz SM, Leibovich BC, Dong H, Lohse CM, Webster WS, Sengupta S, Frank I, Parker AS, Zincke H, et al. Tumor b7-h1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res. 2006;66(7):3381–85.
   PubMed Web of Science ®Google Scholar
• Thompson RH, Dong H, Lohse CM, Leibovich BC, Blute ML, Cheville JC, Kwon ED. Pd-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res. 2007;13(6):1757–61. doi:10.1158/1078-0432.CCR-06-2599.
   PubMed Web of Science ®Google Scholar
• Kang MJ, Kim KM, Bae JS, Park HS, Lee H, Chung MJ, Moon WS, Lee DG, Jang KY. Tumor-infiltrating pd1-positive lymphocytes and foxp3-positive regulatory t cells predict distant metastatic relapse and survival of clear cell renal cell carcinoma. Transl Oncol. 2013;6(3):282–89. doi:10.1593/tlo.13256.
   PubMed Web of Science ®Google Scholar
• Anderson AC, Joller N, Kuchroo VK. Lag-3, tim-3, and tigit: co-inhibitory receptors with specialized functions in immune regulation. Immunity. 2016;44(5):989–1004. doi:10.1016/j.immuni.2016.05.001.
   PubMed Web of Science ®Google Scholar
• Granier C, Dariane C, Combe P, Verkarre V, Urien S, Badoual C, Roussel H, Mandavit M, Ravel P, Sibony M, et al. Tim-3 expression on tumor-infiltrating pd-1(+)cd8(+) t cells correlates with poor clinical outcome in renal cell carcinoma. Cancer Res. 2017;77(5):1075–82. doi:10.1158/0008-5472.CAN-16-0274.
   PubMed Web of Science ®Google Scholar
• Sakuishi K, Ngiow SF, Sullivan JM, Teng MW, Kuchroo VK, Smyth MJ, Anderson AC. Tim3(+)foxp3(+) regulatory t cells are tissue-specific promoters of t-cell dysfunction in cancer. Oncoimmunology. 2013;2(4):e23849. doi:10.4161/onci.23849.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803–13. doi:10.1056/NEJMoa1510665.
   PubMed Web of Science ®Google Scholar
• Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, Xie M, Zhang Q, McMichael JF, Wyczalkowski MA, et al. Mutational landscape and significance across 12 major cancer types. Nature. 2013;502(7471):333–39. doi:10.1038/nature12634.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research N. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. 2013;499(7456):43–49. doi:10.1038/nature12222.
   PubMed Web of Science ®Google Scholar
• de Velasco G, Wankowicz SA, Madison R, Ali SM, Norton C, Duquette A, Ross JS, Bosse D, Lalani AA, Miller VA, et al. Targeted genomic landscape of metastases compared to primary tumours in clear cell metastatic renal cell carcinoma. Br J Cancer. 2018;118(9):1238–42. doi:10.1038/s41416-018-0064-3.
   PubMed Web of Science ®Google Scholar
• Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to pd-1 inhibition. N Engl J Med. 2017;377(25):2500–01. doi:10.1056/NEJMc1713444.
   PubMed Web of Science ®Google Scholar
• Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord JP, Geva R, Gottfried M, Penel N, Hansen AR, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase ii keynote-158 study. J Clin Oncol. 2020;38(1):1–10. doi:10.1200/JCO.19.02105.
   PubMed Web of Science ®Google Scholar
• McDermott DF, Lee J-L, Bjarnason GA, Larkin JMG, Gafanov R, Kochenderfer MD, Jensen NV, Donskov F, Malik J, Poprach A, et al. First-line pembrolizumab (pembro) monotherapy in advanced clear cell renal cell carcinoma (ccrcc): updated follow-up for keynote-427 cohort a. J Clin Oncol. 2020;38(15_suppl):5069–5069.
   Google Scholar
• Turajlic S, Litchfield K, Xu H, Rosenthal R, McGranahan N, Reading JL, Wong YNS, Rowan A, Kanu N, Al Bakir M, et al. Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. Lancet Oncol. 2017;18(8):1009–21. doi:10.1016/S1470-2045(17)30516-8.
   PubMed Web of Science ®Google Scholar
• Braun DA, Hou Y, Bakouny Z, Ficial M, Sant’ Angelo M, Forman J, Ross-Macdonald P, Berger AC, Jegede OA, Elagina L, et al. Interplay of somatic alterations and immune infiltration modulates response to pd-1 blockade in advanced clear cell renal cell carcinoma. Nat Med. 2020;26(6):909–18. doi:10.1038/s41591-020-0839-y.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Choueiri TK, McDermott DF, Powles T, Yao J, Ammar R, Papillon-Cavanagh S, Saggi SS, McHenry BM, Ross-Macdonald P, et al. Biomarker analyses from the phase iii checkmate 214 trial of nivolumab plus ipilimumab (n+i) or sunitinib (s) in advanced renal cell carcinoma (arcc). J Clin Oncol. 2020;38(15_suppl):5009–5009. doi:10.1200/JCO.2020.38.15_suppl.5009.
   Web of Science ®Google Scholar
• Motzer RJ, Robbins PB, Powles T, Albiges L, Haanen JB, Larkin J, Mu XJ, Ching KA, Uemura M, Pal SK, et al. Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 javelin renal 101 trial. Nat Med. 2020;26:1733–41. doi:10.1038/s41591-020-1044-8.
   PubMed Web of Science ®Google Scholar
• McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier B, Fong L, Joseph RW, Pal SK, Reeves JA, et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat Med. 2018;24(6):749–57. doi:10.1038/s41591-018-0053-3.
   PubMed Web of Science ®Google Scholar
• Schmitt K, Reichrath J, Roesch A, Meese E, Mayer J. Transcriptional profiling of human endogenous retrovirus group herv-k(hml-2) loci in melanoma. Genome Biol Evol. 2013;5(2):307–28. doi:10.1093/gbe/evt010.
   PubMed Web of Science ®Google Scholar
• Wang-Johanning F, Liu J, Rycaj K, Huang M, Tsai K, Rosen DG, Chen DT, Lu DW, Barnhart KF, Johanning GL. Expression of multiple human endogenous retrovirus surface envelope proteins in ovarian cancer. Int J Cancer. 2007;120(1):81–90. doi:10.1002/ijc.22256.
   PubMed Web of Science ®Google Scholar
• Contreras-Galindo R, Kaplan MH, Leissner P, Verjat T, Ferlenghi I, Bagnoli F, Giusti F, Dosik MH, Hayes DF, Gitlin SD, et al. Human endogenous retrovirus k (hml-2) elements in the plasma of people with lymphoma and breast cancer. J Virol. 2008;82(19):9329–36. doi:10.1128/JVI.00646-08.
   PubMed Web of Science ®Google Scholar
• Florl AR, Lower R, Schmitz-Drager BJ, Schulz WA. DNA methylation and expression of line-1 and herv-k provirus sequences in urothelial and renal cell carcinomas. Br J Cancer. 1999;80(9):1312–21. doi:10.1038/sj.bjc.6690524.
   PubMed Web of Science ®Google Scholar
• Siebenthall KT, Miller CP, Vierstra JD, Mathieu J, Tretiakova M, Reynolds A, Sandstrom R, Rynes E, Haugen E, Johnson A, et al. Integrated epigenomic profiling reveals endogenous retrovirus reactivation in renal cell carcinoma. EBioMedicine. 2019;41:427–42. doi:10.1016/j.ebiom.2019.01.063.
   PubMed Web of Science ®Google Scholar
• Cherkasova E, Malinzak E, Rao S, Takahashi Y, Senchenko VN, Kudryavtseva AV, Nickerson ML, Merino M, Hong JA, Schrump DS, et al. Inactivation of the von hippel-lindau tumor suppressor leads to selective expression of a human endogenous retrovirus in kidney cancer. Oncogene. 2011;30(47):4697–706. doi:10.1038/onc.2011.179.
   PubMed Web of Science ®Google Scholar
• Takahashi Y, Harashima N, Kajigaya S, Yokoyama H, Cherkasova E, McCoy JP, Hanada K, Mena O, Kurlander R, Tawab A, et al. Regression of human kidney cancer following allogeneic stem cell transplantation is associated with recognition of an herv-e antigen by t cells. J Clin Invest. 2008;118(3):1099–109. doi:10.1172/JCI34409C1.
   PubMed Web of Science ®Google Scholar
• Cherkasova E, Scrivani C, Doh S, Weisman Q, Takahashi Y, Harashima N, Yokoyama H, Srinivasan R, Linehan WM, Lerman MI, et al. Detection of an immunogenic herv-e envelope with selective expression in clear cell kidney cancer. Cancer Res. 2016;76(8):2177–85. doi:10.1158/0008-5472.CAN-15-3139.
   PubMed Web of Science ®Google Scholar
• Smith CC, Selitsky SR, Chai S, Armistead PM, Vincent BG, Serody JS. Alternative tumour-specific antigens. Nat Rev Cancer. 2019;19(8):465–78. doi:10.1038/s41568-019-0162-4.
   PubMed Web of Science ®Google Scholar
• Smith CC, Beckermann KE, Bortone DS, De Cubas AA, Bixby LM, Lee SJ, Panda A, Ganesan S, Bhanot G, Wallen EM, et al. Endogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma. J Clin Invest. 2018;128(11):4804–20. doi:10.1172/JCI121476.
   PubMed Web of Science ®Google Scholar
• Pignon J-C, Jegede O, Shukla SA, Braun DA, Horak C, Wind-Rotolo M, Ishii Y, Catalano PJ, Freeman GJ, Jennings RB, et al. Association of human endogenous retrovirus (herv) expression with clinical efficacy of pd-1 blockade in metastatic clear cell renal cell carcinoma (mccrcc). J Clin Oncol. 2019;37(15_suppl):4568–4568. doi:10.1200/JCO.2019.37.15_suppl.4568.
   Web of Science ®Google Scholar
• Uemura H, Fujimoto K, Tanaka M, Yoshikawa M, Hirao Y, Uejima S, Yoshikawa K, Itoh K. A phase i trial of vaccination of ca9-derived peptides for hla-a24-positive patients with cytokine-refractory metastatic renal cell carcinoma. Clin Cancer Res. 2006;12(6):1768–75. doi:10.1158/1078-0432.CCR-05-2253.
   PubMed Web of Science ®Google Scholar
• Bleumer I, Tiemessen DM, Oosterwijk-Wakka JC, Voller MC, De Weijer K, Mulders PF, Oosterwijk E. Preliminary analysis of patients with progressive renal cell carcinoma vaccinated with ca9-peptide-pulsed mature dendritic cells. J Immunother. 2007;30(1):116–22. doi:10.1097/01.cji.0000211318.22902.ec.
   PubMed Web of Science ®Google Scholar
• Lamers CH, Sleijfer S, van Steenbergen S, van Elzakker P, van Krimpen B, Groot C, Vulto A, den Bakker M, Oosterwijk E, Debets R, et al. Treatment of metastatic renal cell carcinoma with caix car-engineered t cells: clinical evaluation and management of on-target toxicity. Mol Ther. 2013;21(4):904–12. doi:10.1038/mt.2013.17.
   PubMed Web of Science ®Google Scholar
• Yoshimura K, Minami T, Nozawa M, Uemura H. Phase i clinical trial of human vascular endothelial growth factor receptor 1 peptide vaccines for patients with metastatic renal cell carcinoma. Br J Cancer. 2013;108(6):1260–66. doi:10.1038/bjc.2013.90.
   PubMed Web of Science ®Google Scholar
• Obara W, Karashima T, Takeda K, Kato R, Kato Y, Kanehira M, Takata R, Inoue K, Katagiri T, Shuin T, et al. Effective induction of cytotoxic t cells recognizing an epitope peptide derived from hypoxia-inducible protein 2 (hig2) in patients with metastatic renal cell carcinoma. Cancer Immunol Immunother. 2017;66(1):17–24. doi:10.1007/s00262-016-1915-5.
   PubMed Web of Science ®Google Scholar
• Rahma OE, Ashtar E, Ibrahim R, Toubaji A, Gause B, Herrin VE, Linehan WM, Steinberg SM, Grollman F, Grimes G, et al. A pilot clinical trial testing mutant von hippel-lindau peptide as a novel immune therapy in metastatic renal cell carcinoma. J Transl Med. 2010;8(1):8. doi:10.1186/1479-5876-8-8.
   PubMed Web of Science ®Google Scholar
• Amato RJ, Shingler W, Naylor S, Jac J, Willis J, Saxena S, Hernandez-McClain J, Harrop R. Vaccination of renal cell cancer patients with modified vaccinia ankara delivering tumor antigen 5t4 (trovax) administered with interleukin 2: A phase ii trial. Clin Cancer Res. 2008;14(22):7504–10. doi:10.1158/1078-0432.CCR-08-0668.
   PubMed Web of Science ®Google Scholar
• Kaufman HL, Taback B, Sherman W, Kim DW, Shingler WH, Moroziewicz D, DeRaffele G, Mitcham J, Carroll MW, Harrop R, et al. Phase ii trial of modified vaccinia ankara (mva) virus expressing 5t4 and high dose interleukin-2 (il-2) in patients with metastatic renal cell carcinoma. J Transl Med. 2009;7(2). doi:10.1186/1479-5876-7-2.
   PubMed Web of Science ®Google Scholar
• Hawkins RE, Macdermott C, Shablak A, Hamer C, Thistlethwaite F, Drury NL, Chikoti P, Shingler W, Naylor S, Harrop R. Vaccination of patients with metastatic renal cancer with modified vaccinia ankara encoding the tumor antigen 5t4 (trovax) given alongside interferon-alpha. J Immunother. 2009;32(4):424–29. doi:10.1097/CJI.0b013e31819d297e.
   PubMed Web of Science ®Google Scholar
• Amato RJ, Shingler W, Goonewardena M, de Belin J, Naylor S, Jac J, Willis J, Saxena S, Hernandez-McClain J, Harrop R. Vaccination of renal cell cancer patients with modified vaccinia ankara delivering the tumor antigen 5t4 (trovax) alone or administered in combination with interferon-alpha (ifn-alpha): A phase 2 trial. J Immunother. 2009;32(7):765–72. doi:10.1097/CJI.0b013e3181ace876.
   PubMed Web of Science ®Google Scholar
• Amato RJ, Hawkins RE, Kaufman HL, Thompson JA, Tomczak P, Szczylik C, McDonald M, Eastty S, Shingler WH, de Belin J, et al. Vaccination of metastatic renal cancer patients with mva-5t4: A randomized, double-blind, placebo-controlled phase iii study. Clin Cancer Res. 2010;16(22):5539–47. doi:10.1158/1078-0432.CCR-10-2082.
   PubMed Web of Science ®Google Scholar
• Wierecky J, Muller MR, Wirths S, Halder-Oehler E, Dorfel D, Schmidt SM, Hantschel M, Brugger W, Schroder S, Horger MS, et al. Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. Cancer Res. 2006;66(11):5910–18. doi:10.1158/0008-5472.CAN-05-3905.
   PubMed Web of Science ®Google Scholar
• Oudard S, Rixe O, Beuselinck B, Linassier C, Banu E, Machiels JP, Baudard M, Ringeisen F, Velu T, Lefrere-Belda MA, et al. A phase ii study of the cancer vaccine tg4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findings. Cancer Immunol Immunother. 2011;60(2):261–71. doi:10.1007/s00262-010-0935-9.
   PubMed Web of Science ®Google Scholar
• Iiyama T, Udaka K, Takeda S, Takeuchi T, Adachi YC, Ohtsuki Y, Tsuboi A, Nakatsuka S, Elisseeva OA, Oji Y, et al. Wt1 (wilms’ tumor 1) peptide immunotherapy for renal cell carcinoma. Microbiol Immunol. 2007;51(5):519–30. doi:10.1111/j.1348-0421.2007.tb03940.x.
   PubMed Web of Science ®Google Scholar
• Ogasawara M, Miyashita M, Ota S. Vaccination of urological cancer patients with wt1 peptide-pulsed dendritic cells in combination with molecular targeted therapy or conventional chemotherapy induces immunological and clinical responses. Ther Apher Dial. 2018;22(3):266–77. doi:10.1111/1744-9987.12694.
   PubMed Web of Science ®Google Scholar
• Suekane S, Nishitani M, Noguchi M, Komohara Y, Kokubu T, Naitoh M, Honma S, Yamada A, Itoh K, Matsuoka K, et al. Phase i trial of personalized peptide vaccination for cytokine-refractory metastatic renal cell carcinoma patients. Cancer Sci. 2007;98(12):1965–68. doi:10.1111/j.1349-7006.2007.00631.x.
   PubMed Web of Science ®Google Scholar
• Berntsen A, Trepiakas R, Wenandy L, Geertsen PF, Thor Straten P, Andersen MH, Pedersen AE, Claesson MH, Lorentzen T, Johansen JS, et al. Therapeutic dendritic cell vaccination of patients with metastatic renal cell carcinoma: a clinical phase 1/2 trial. J Immunother. 2008;31(8):771–80. doi:10.1097/CJI.0b013e3181833818.
   PubMed Web of Science ®Google Scholar
• Walter S, Weinschenk T, Stenzl A, Zdrojowy R, Pluzanska A, Szczylik C, Staehler M, Brugger W, Dietrich PY, Mendrzyk R, et al. Multipeptide immune response to cancer vaccine ima901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med. 2012;18(8):1254–61. doi:10.1038/nm.2883.
   PubMed Web of Science ®Google Scholar
• Rini BI, Stenzl A, Zdrojowy R, Kogan M, Shkolnik M, Oudard S, Weikert S, Bracarda S, Crabb SJ, Bedke J, et al. Ima901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (imprint): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2016;17(11):1599–611. doi:10.1016/S1470-2045(16)30408-9.
   PubMed Web of Science ®Google Scholar
• Amin A, Dudek AZ, Logan TF, Lance RS, Holzbeierlein JM, Knox JJ, Master VA, Pal SK, Miller WH Jr., Karsh LI, et al. Survival with ags-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (rcc): phase 2 study results. J Immunother Cancer. 2015;3(14). doi:10.1186/s40425-015-0055-3.
   PubMed Web of Science ®Google Scholar
• Figlin RA, Tannir NM, Uzzo RG, Tykodi SS, Chen DYT, Master V, Kapoor A, Vaena D, Lowrance WT, Bratslavsky G, et al. Results of the adapt phase 3 study of rocapuldencel-t in combination with sunitinib as first-line therapy in patients with metastatic renal cell carcinoma. Clin Cancer Res. 2020;26:2327–36. doi:10.1158/1078-0432.CCR-19-2427.
   PubMed Web of Science ®Google Scholar
• Oosterwijk E, Ruiter DJ, Hoedemaeker PJ, Pauwels EK, Jonas U, Zwartendijk J, Warnaar SO. Monoclonal antibody g 250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney. Int J Cancer. 1986;38(4):489–94. doi:10.1002/ijc.2910380406.
   PubMed Web of Science ®Google Scholar
• Pastorek J, Pastorekova S. Hypoxia-induced carbonic anhydrase ix as a target for cancer therapy: from biology to clinical use. Semin Cancer Biol. 2015;31:52–64. doi:10.1016/j.semcancer.2014.08.002.
   PubMed Web of Science ®Google Scholar
• Mandriota SJ, Turner KJ, Davies DR, Murray PG, Morgan NV, Sowter HM, Wykoff CC, Maher ER, Harris AL, Ratcliffe PJ, et al. Hif activation identifies early lesions in vhl kidneys: evidence for site-specific tumor suppressor function in the nephron. Cancer Cell. 2002;1(5):459–68. doi:10.1016/S1535-6108(02)00071-5.
   PubMed Web of Science ®Google Scholar
• Ivanov S, Liao SY, Ivanova A, Danilkovitch-Miagkova A, Tarasova N, Weirich G, Merrill MJ, Proescholdt MA, Oldfield EH, Lee J, et al. Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am J Pathol. 2001;158(3):905–19.
   PubMed Web of Science ®Google Scholar
• Vissers JL, De Vries IJ, Schreurs MW, Engelen LP, Oosterwijk E, Figdor CG, Adema GJ. The renal cell carcinoma-associated antigen g250 encodes a human leukocyte antigen (hla)-a2.1-restricted epitope recognized by cytotoxic t lymphocytes. Cancer Res. 1999;59:5554–59.
   PubMed Web of Science ®Google Scholar
• Vissers JL, De Vries IJ, Engelen LP, Scharenborg NM, Molkenboer J, Figdor CG, Oosterwijk E, Adema GJ. Renal cell carcinoma-associated antigen g250 encodes a naturally processed epitope presented by human leukocyte antigen-dr molecules to cd4(+) t lymphocytes. Int J Cancer. 2002;100(4):441–44. doi:10.1002/ijc.10518.
   PubMed Web of Science ®Google Scholar
• Li H, Ding J, Lu M, Liu H, Miao Y, Li L, Wang G, Zheng J, Pei D, Zhang Q. Caix-specific car-t cells and sunitinib show synergistic effects against metastatic renal cancer models. J Immunother. 2020;43(1):16–28. doi:10.1097/CJI.0000000000000301.
   PubMed Web of Science ®Google Scholar
• Togashi A, Katagiri T, Ashida S, Fujioka T, Maruyama O, Wakumoto Y, Sakamoto Y, Fujime M, Kawachi Y, Shuin T, et al. Hypoxia-inducible protein 2 (hig2), a novel diagnostic marker for renal cell carcinoma and potential target for molecular therapy. Cancer Res. 2005;65(11):4817–26. doi:10.1158/0008-5472.CAN-05-0120.
   PubMed Web of Science ®Google Scholar
• Soga N, Hori Y, Yamakado K, Ikeda H, Imai N, Kageyama S, Nakase K, Yuta A, Hayashi N, Shiku H, et al. Limited expression of cancer-testis antigens in renal cell carcinoma patients. Mol Clin Oncol. 2013;1(2):326–30. doi:10.3892/mco.2012.40.
   PubMedGoogle Scholar
• Griffiths RW, Gilham DE, Dangoor A, Ramani V, Clarke NW, Stern PL, Hawkins RE. Expression of the 5t4 oncofoetal antigen in renal cell carcinoma: a potential target for t-cell-based immunotherapy. Br J Cancer. 2005;93(6):670–77. doi:10.1038/sj.bjc.6602776.
   PubMed Web of Science ®Google Scholar
• Stern PL, Harrop R. 5t4 oncofoetal antigen: an attractive target for immune intervention in cancer. Cancer Immunol Immunother. 2017;66(4):415–26. doi:10.1007/s00262-016-1917-3.
   PubMed Web of Science ®Google Scholar
• Southall PJ, Boxer GM, Bagshawe KD, Hole N, Bromley M, Stern PL. Immunohistological distribution of 5t4 antigen in normal and malignant tissues. Br J Cancer. 1990;61(1):89–95. doi:10.1038/bjc.1990.20.
   PubMed Web of Science ®Google Scholar
• Smyth LJ, Elkord E, Taher TE, Jiang HR, Burt DJ, Clayton A, van Veelen PA, de Ru A, Ossendorp F, Melief CJ, et al. Cd8 t-cell recognition of human 5t4 oncofetal antigen. Int J Cancer. 2006;119(7):1638–47. doi:10.1002/ijc.22018.
   PubMed Web of Science ®Google Scholar
• Elkord E, Burt DJ, Drijfhout JW, Hawkins RE, Stern PL. Cd4+ t-cell recognition of human 5t4 oncofoetal antigen: implications for initial depletion of cd25+ t cells. Cancer Immunol Immunother. 2008;57(6):833–47. doi:10.1007/s00262-007-0419-8.
   PubMed Web of Science ®Google Scholar
• Shingler WH, Chikoti P, Kingsman SM, Harrop R. Identification and functional validation of mhc class i epitopes in the tumor-associated antigen 5t4. Int Immunol. 2008;20(8):1057–66. doi:10.1093/intimm/dxn063.
   PubMed Web of Science ®Google Scholar
• Redchenko I, Harrop R, Ryan MG, Hawkins RE, Carroll MW. Identification of a major histocompatibility complex class i-restricted t-cell epitope in the tumour-associated antigen, 5t4. Immunology. 2006;118(1):50–57. doi:10.1111/j.1365-2567.2006.02338.x.
   PubMed Web of Science ®Google Scholar
• Said R, Amato RJ. Identification of pre- and post-treatment markers, clinical, and laboratory parameters associated with outcome in renal cancer patients treated with mva-5t4. Front Oncol. 2013;3(185). doi:10.3389/fonc.2013.00185.
   PubMedGoogle Scholar
• Elkord E, Dangoor A, Drury NL, Harrop R, Burt DJ, Drijfhout JW, Hamer C, Andrews D, Naylor S, Sherlock D, et al. An mva-based vaccine targeting the oncofetal antigen 5t4 in patients undergoing surgical resection of colorectal cancer liver metastases. J Immunother. 2008;31(9):820–29. doi:10.1097/CJI.0b013e3181876ab3.
   PubMed Web of Science ®Google Scholar
• Harrop R, Connolly N, Redchenko I, Valle J, Saunders M, Ryan MG, Myers KA, Drury N, Kingsman SM, Hawkins RE, et al. Vaccination of colorectal cancer patients with modified vaccinia ankara delivering the tumor antigen 5t4 (trovax) induces immune responses which correlate with disease control: a phase i/ii trial. Clin Cancer Res. 2006;12(11 Pt 1):3416–24. doi:10.1158/1078-0432.CCR-05-2732.
   PubMed Web of Science ®Google Scholar
• Forsberg G, Skartved NJ, Wallen-Ohman M, Nyhlen HC, Behm K, Hedlund G, Nederman T. Naptumomab estafenatox, an engineered antibody-superantigen fusion protein with low toxicity and reduced antigenicity. J Immunother. 2010;33(5):492–99. doi:10.1097/CJI.0b013e3181d75820.
   PubMed Web of Science ®Google Scholar
• Hawkins RE, Gore M, Shparyk Y, Bondar V, Gladkov O, Ganev T, Harza M, Polenkov S, Bondarenko I, Karlov P, et al. A randomized phase ii/iii study of naptumomab estafenatox + ifnalpha versus ifnalpha in renal cell carcinoma: final analysis with baseline biomarker subgroup and trend analysis. Clin Cancer Res. 2016;22(13):3172–81. doi:10.1158/1078-0432.CCR-15-0580.
   PubMed Web of Science ®Google Scholar
• Elkord E, Burt DJ, Sundstedt A, Nordle O, Hedlund G, Hawkins RE. Immunological response and overall survival in a subset of advanced renal cell carcinoma patients from a randomized phase 2/3 study of naptumomab estafenatox plus ifn-alpha versus ifn-alpha. Oncotarget. 2015;6(6):4428–39. doi:10.18632/oncotarget.2922.
   PubMedGoogle Scholar
• Leroy X, Zerimech F, Zini L, Copin MC, Buisine MP, Gosselin B, Aubert JP, Porchet N. Muc1 expression is correlated with nuclear grade and tumor progression in pt1 renal clear cell carcinoma. Am J Clin Pathol. 2002;118(1):47–51. doi:10.1309/1F99-BPDY-7DHH-9G97.
   PubMed Web of Science ®Google Scholar
• Pinho SS, Reis CA. Glycosylation in cancer: mechanisms and clinical implications. Nat Rev Cancer. 2015;15:540–55.
   PubMed Web of Science ®Google Scholar
• Kraus S, Abel PD, Nachtmann C, Linsenmann HJ, Weidner W, Stamp GW, Chaudhary KS, Mitchell SE, Franke FE, Lalani El N. Muc1 mucin and trefoil factor 1 protein expression in renal cell carcinoma: correlation with prognosis. Hum Pathol. 2002;33(1):60–67. doi:10.1053/hupa.2002.29682.
   PubMed Web of Science ®Google Scholar
• Fujita K, Denda K, Yamamoto M, Matsumoto T, Fujime M, Irimura T. Expression of muc1 mucins inversely correlated with post-surgical survival of renal cell carcinoma patients. Br J Cancer. 1999;80(1–2):301–08. doi:10.1038/sj.bjc.6690355.
   PubMed Web of Science ®Google Scholar
• Roulois D, Gregoire M, Fonteneau JF. Muc1-specific cytotoxic t lymphocytes in cancer therapy: induction and challenge. Biomed Res Int. 2013;(2013):871936. doi:10.1155/2013/871936.
   PubMed Web of Science ®Google Scholar
• Brossart P, Heinrich KS, Stuhler G, Behnke L, Reichardt VL, Stevanovic S, Muhm A, Rammensee HG, Kanz L, Brugger W. Identification of hla-a2-restricted t-cell epitopes derived from the muc1 tumor antigen for broadly applicable vaccine therapies. Blood. 1999;93(12):4309–17. doi:10.1182/blood.V93.12.4309.
   PubMed Web of Science ®Google Scholar
• Ninkovic T, Kinarsky L, Engelmann K, Pisarev V, Sherman S, Finn OJ, Hanisch FG. Identification of o-glycosylated decapeptides within the muc1 repeat domain as potential mhc class i (a2) binding epitopes. Mol Immunol. 2009;47(1):131–40. doi:10.1016/j.molimm.2008.09.032.
   PubMed Web of Science ®Google Scholar
• Brossart P, Schneider A, Dill P, Schammann T, Grunebach F, Wirths S, Kanz L, Buhring HJ, Brugger W. The epithelial tumor antigen muc1 is expressed in hematological malignancies and is recognized by muc1-specific cytotoxic t-lymphocytes. Cancer Res. 2001;61:6846–50.
   PubMed Web of Science ®Google Scholar
• Scheikl-Gatard T, Tosch C, Lemonnier F, Rooke R. Identification of new muc1 epitopes using hla-transgenic animals: implication for immunomonitoring. J Transl Med. 2017;15(1):154. doi:10.1186/s12967-017-1254-0.
   PubMed Web of Science ®Google Scholar
• Barnd DL, Lan MS, Metzgar RS, Finn OJ. Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic t cells. Proc Natl Acad Sci U S A. 1989;86(18):7159–63. doi:10.1073/pnas.86.18.7159.
   PubMed Web of Science ®Google Scholar
• Ramanathan RK, Lee KM, McKolanis J, Hitbold E, Schraut W, Moser AJ, Warnick E, Whiteside T, Osborne J, Kim H, et al. Phase i study of a muc1 vaccine composed of different doses of muc1 peptide with sb-as2 adjuvant in resected and locally advanced pancreatic cancer. Cancer Immunol Immunother. 2005;54(3):254–64. doi:10.1007/s00262-004-0581-1.
   PubMed Web of Science ®Google Scholar
• Rochlitz C, Figlin R, Squiban P, Salzberg M, Pless M, Herrmann R, Tartour E, Zhao Y, Bizouarne N, Baudin M, et al. Phase i immunotherapy with a modified vaccinia virus (mva) expressing human muc1 as antigen-specific immunotherapy in patients with muc1-positive advanced cancer. J Gene Med. 2003;5(8):690–99. doi:10.1002/jgm.397.
   PubMed Web of Science ®Google Scholar
• Quoix E, Ramlau R, Westeel V, Papai Z, Madroszyk A, Riviere A, Koralewski P, Breton JL, Stoelben E, Braun D, et al. Therapeutic vaccination with tg4010 and first-line chemotherapy in advanced non-small-cell lung cancer: A controlled phase 2b trial. Lancet Oncol. 2011;12(12):1125–33. doi:10.1016/S1470-2045(11)70259-5.
   PubMed Web of Science ®Google Scholar
• Nakatsuka S, Oji Y, Horiuchi T, Kanda T, Kitagawa M, Takeuchi T, Kawano K, Kuwae Y, Yamauchi A, Okumura M, et al. Immunohistochemical detection of wt1 protein in a variety of cancer cells. Mod Pathol. 2006;19(6):804–14. doi:10.1038/modpathol.3800588.
   PubMed Web of Science ®Google Scholar
• Okamoto M, Furuichi S, Nishioka Y, Oshikawa T, Tano T, Ahmed SU, Takeda K, Akira S, Ryoma Y, Moriya Y, et al. Expression of toll-like receptor 4 on dendritic cells is significant for anticancer effect of dendritic cell-based immunotherapy in combination with an active component of ok-432, a streptococcal preparation. Cancer Res. 2004;64(15):5461–70. doi:10.1158/0008-5472.CAN-03-4005.
   PubMed Web of Science ®Google Scholar
• Parker AS, Leibovich BC, Lohse CM, Sheinin Y, Kuntz SM, Eckel-Passow JE, Blute ML, Kwon ED, Parker AS, Leibovich BC, et al. Development and evaluation of bioscore: A biomarker panel to enhance prognostic algorithms for clear cell renal cell carcinoma. Cancer. 2009;115(10):2092–103. doi:10.1002/cncr.24263.
   PubMed Web of Science ®Google Scholar
• Xie Y, Ma X, Gu L, Li H, Chen L, Li X, Gao Y, Fan Y, Zhang Y, Yao Y, et al. Prognostic and clinicopathological significance of survivin expression in renal cell carcinoma: A systematic review and meta-analysis. Sci Rep. 2016;6:29794. doi:10.1038/srep29794.
   Web of Science ®Google Scholar
• Weinschenk T, Gouttefangeas C, Schirle M, Obermayr F, Walter S, Schoor O, Kurek R, Loeser W, Bichler KH, Wernet D, et al. Integrated functional genomics approach for the design of patient-individual antitumor vaccines. Cancer Res. 2002;62(20):5818–27.
   PubMed Web of Science ®Google Scholar
• Kirner A, Mayer-Mokler A, Reinhardt C. Ima901: A multi-peptide cancer vaccine for treatment of renal cell cancer. Hum Vaccin Immunother. 2014;10(11):3179–89. doi:10.4161/21645515.2014.983857.
   PubMed Web of Science ®Google Scholar
• Su Z, Dannull J, Heiser A, Yancey D, Pruitt S, Madden J, Coleman D, Niedzwiecki D, Gilboa E, Vieweg J. Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor rna-transfected dendritic cells. Cancer Res. 2003;63:2127–33.
   PubMed Web of Science ®Google Scholar
• Calderhead DM, DeBenedette MA, Ketteringham H, Gamble AH, Horvatinovich JM, Tcherepanova IY, Nicolette CA, Healey DG. Cytokine maturation followed by cd40l mrna electroporation results in a clinically relevant dendritic cell product capable of inducing a potent proinflammatory ctl response. J Immunother. 2008;31(8):731–41. doi:10.1097/CJI.0b013e318183db02.
   PubMed Web of Science ®Google Scholar
• Cappuccini F, Pollock E, Stribbling S, Hill AVS, Redchenko I. 5t4 oncofoetal glycoprotein: an old target for a novel prostate cancer immunotherapy. Oncotarget. 2017;8(29):47474–89. doi:10.18632/oncotarget.17666.
   PubMedGoogle Scholar
• Cappuccini F, Bryant R, Pollock E, Carter L, Verrill C, Hollidge J, Poulton I, Baker M, Mitton C, Baines A, et al. Safety and immunogenicity of novel 5t4 viral vectored vaccination regimens in early stage prostate cancer: A phase i clinical trial. J Immunother Cancer. 2020;8(1):e000928. doi:10.1136/jitc-2020-000928.
   PubMed Web of Science ®Google Scholar
• Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, Teachey DT, Chew A, Hauck B, Wright JF, et al. Chimeric antigen receptor-modified t cells for acute lymphoid leukemia. N Engl J Med. 2013;368(16):1509–18. doi:10.1056/NEJMoa1215134.
   PubMed Web of Science ®Google Scholar
• Turtle CJ, Hanafi LA, Berger C, Hudecek M, Pender B, Robinson E, Hawkins R, Chaney C, Cherian S, Chen X, et al. Immunotherapy of non-hodgkin’s lymphoma with a defined ratio of cd8+ and cd4+ cd19-specific chimeric antigen receptor-modified t cells. Sci Transl Med. 2016;8(355):355ra116. doi:10.1126/scitranslmed.aaf8621.
   PubMed Web of Science ®Google Scholar
• Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, Wunderlich JR, Nahvi AV, Helman LJ, Mackall CL, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with ny-eso-1. J Clin Oncol. 2011;29(7):917–24. doi:10.1200/JCO.2010.32.2537.
   PubMed Web of Science ®Google Scholar
• Doran SL, Stevanovic S, Adhikary S, Gartner JJ, Jia L, Kwong MLM, Faquin WC, Hewitt SM, Sherry RM, Yang JC, et al. T-cell receptor gene therapy for human papillomavirus-associated epithelial cancers: a first-in-human, phase i/ii study. J Clin Oncol. 2019;37(30):2759–68. doi:10.1200/JCO.18.02424.
   PubMed Web of Science ®Google Scholar
• Hong DS, Van Tine BA, Olszanski AJ, Johnson ML, Liebner DA, Trivedi T, Lin Q, Elefant E, Dryer-Minnerly R, Navenot J-M, et al. Phase I dose escalation and expansion trial to assess the safety and efficacy of ADP-A2M4 SPEAR T cells in advanced solid tumors. J. Clin. Oncol. 2020;38(15_suppl):102. doi:10.1200/JCO.2020.38.15_suppl.102.
   Google Scholar
• Thomas S, Mohammed F, Reijmers RM, Woolston A, Stauss T, Kennedy A, Stirling D, Holler A, Green L, Jones D, et al. Framework engineering to produce dominant t cell receptors with enhanced antigen-specific function. Nat Commun. 2019;10(1):4451. doi:10.1038/s41467-019-12441-w.
   PubMed Web of Science ®Google Scholar
• Weinkove R, George P, Dasyam N, McLellan AD. Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations. Clin Transl Immunol. 2019;8(5):e1049. doi:10.1002/cti2.1049.
   PubMed Web of Science ®Google Scholar
• Yang Y, Kohler ME, Chien CD, Sauter CT, Jacoby E, Yan C, Hu Y, Wanhainen K, Qin H, Fry TJ. Tcr engagement negatively affects cd8 but not cd4 car t cell expansion and leukemic clearance. Sci Transl Med. 2017;9(417):eaag1209. doi:10.1126/scitranslmed.aag1209.
   PubMed Web of Science ®Google Scholar
• Wang X, Popplewell LL, Wagner JR, Naranjo A, Blanchard MS, Mott MR, Norris AP, Wong CW, Urak RZ, Chang WC, et al. Phase 1 studies of central memory-derived cd19 car t-cell therapy following autologous hsct in patients with b-cell nhl. Blood. 2016;127(24):2980–90. doi:10.1182/blood-2015-12-686725.
   PubMed Web of Science ®Google Scholar
• Morton LT, Reijmers RM, Wouters AK, Kweekel C, Remst DFG, Pothast CR, Falkenburg JHF, Heemskerk MHM. Simultaneous deletion of endogenous tcralphabeta for tcr gene therapy creates an improved and safe cellular therapeutic. Mol Ther. 2020;28(1):64–74. doi:10.1016/j.ymthe.2019.10.001.
   PubMed Web of Science ®Google Scholar
• Stadtmauer EA, Fraietta JA, Davis MM, Cohen AD, Weber KL, Lancaster E, Mangan PA, Kulikovskaya I, Gupta M, Chen F, et al. Crispr-engineered t cells in patients with refractory cancer. Science. 2020;367(6481):eaba7365. doi:10.1126/science.aba7365.
   PubMed Web of Science ®Google Scholar
• Xu Y, Morales AJ, Cargill MJ, Towlerton AMH, Coffey DG, Warren EH, Tykodi SS. Preclinical development of t-cell receptor-engineered t-cell therapy targeting the 5t4 tumor antigen on renal cell carcinoma. Cancer Immunol Immunother. 2019;68(12):1979–93. doi:10.1007/s00262-019-02419-4.
   PubMed Web of Science ®Google Scholar
• Yossef R, Tran E, Deniger DC, Gros A, Pasetto A, Parkhurst MR, Gartner JJ, Prickett TD, Cafri G, Robbins PF, et al. Enhanced detection of neoantigen-reactive t cells targeting unique and shared oncogenes for personalized cancer immunotherapy. JCI Insight. 2018;3(19). doi:10.1172/jci.insight.122467.
   PubMed Web of Science ®Google Scholar
• Kula T, Dezfulian MH, Wang CI, Abdelfattah NS, Hartman ZC, Wucherpfennig KW, Lyerly HK, Elledge SJ. T-scan: a genome-wide method for the systematic discovery of t cell epitopes. Cell. 2019;178(4):1016–1028 e1013. doi:10.1016/j.cell.2019.07.009.
   PubMed Web of Science ®Google Scholar
• Gee MH, Han A, Lofgren SM, Beausang JF, Mendoza JL, Birnbaum ME, Bethune MT, Fischer S, Yang X, Gomez-Eerland R, et al. Antigen identification for orphan t cell receptors expressed on tumor-infiltrating lymphocytes. Cell. 2018;172(3):549–563 e516. doi:10.1016/j.cell.2017.11.043.
   PubMed Web of Science ®Google Scholar
• Crowther MD, Dolton G, Legut M, Caillaud ME, Lloyd A, Attaf M, Galloway SAE, Rius C, Farrell CP, Szomolay B, et al. Genome-wide crispr-cas9 screening reveals ubiquitous t cell cancer targeting via the monomorphic mhc class i-related protein mr1. Nat Immunol. 2020;21(2):178–85. doi:10.1038/s41590-019-0578-8.
   PubMed Web of Science ®Google Scholar
• Patel SJ, Sanjana NE, Kishton RJ, Eidizadeh A, Vodnala SK, Cam M, Gartner JJ, Jia L, Steinberg SM, Yamamoto TN, et al. Identification of essential genes for cancer immunotherapy. Nature. 2017;548(7669):537–42. doi:10.1038/nature23477.
   PubMed Web of Science ®Google Scholar